FDA Panel Narrowly Backs New Use of UCB, Inc.'s Arthritis Drug
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favour of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis. While the vote was not binding on a final recommendation, it would play a part in the decision to clear the drug for this application in the United States, UCB said.
Help employers find you! Check out all the jobs and post your resume.
Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favour of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis. While the vote was not binding on a final recommendation, it would play a part in the decision to clear the drug for this application in the United States, UCB said.
Help employers find you! Check out all the jobs and post your resume.